Anti-PD-L1 mAb combined with VEGFR2 small molecule inhibitor can significantly downregulate the expression of PD-1 and PD-L1, increase tumor-infiltrating lymphocytes, and inhibit tumor growth by reducing Tregs and MDSCs [102]. The gene discussed is KDR; the disease is neoplasm.